CME Group Inc. (NASDAQ:CME) Shares Purchased by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC lifted its holdings in CME Group Inc. (NASDAQ:CME - Free Report) by 0.9% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 196,036 shares of the financial services provider's stock after acquiring an additional 1,801 shares during the quarter. Allspring Global Investments Holdings LLC owned 0.05% of CME Group worth $51,408,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Alpine Bank Wealth Management acquired a new stake in shares of CME Group in the first quarter worth $32,000. New Age Alpha Advisors LLC grew its position in CME Group by 50.0% during the fourth quarter. New Age Alpha Advisors LLC now owns 129 shares of the financial services provider's stock valued at $30,000 after buying an additional 43 shares during the period. Knuff & Co LLC acquired a new stake in CME Group during the fourth quarter valued at $33,000. Banque Transatlantique SA acquired a new stake in CME Group during the fourth quarter valued at $35,000. Finally, Whipplewood Advisors LLC acquired a new stake in CME Group during the fourth quarter valued at $37,000. Institutional investors and hedge funds own 87.75% of the company's stock.

CME Group Stock Performance

NASDAQ:CME opened at $274.76 on Monday. The company's 50-day moving average price is $275.21 and its 200-day moving average price is $256.83. The company has a current ratio of 1.02, a quick ratio of 1.02 and a debt-to-equity ratio of 0.13. The company has a market cap of $99.01 billion, a P/E ratio of 27.64, a P/E/G ratio of 3.73 and a beta of 0.45. CME Group Inc. has a twelve month low of $193.17 and a twelve month high of $290.79.

CME Group (NASDAQ:CME - Get Free Report) last posted its quarterly earnings results on Wednesday, April 23rd. The financial services provider reported $2.80 earnings per share for the quarter, topping the consensus estimate of $2.61 by $0.19. The firm had revenue of $1.64 billion for the quarter, compared to the consensus estimate of $1.56 billion. CME Group had a net margin of 57.71% and a return on equity of 14.03%. The company's revenue for the quarter was up 10.4% on a year-over-year basis. During the same period last year, the firm posted $2.50 earnings per share. On average, sell-side analysts forecast that CME Group Inc. will post 10.49 earnings per share for the current fiscal year.

CME Group Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Wednesday, June 25th. Stockholders of record on Monday, June 9th were paid a $1.25 dividend. This represents a $5.00 annualized dividend and a dividend yield of 1.82%. The ex-dividend date was Monday, June 9th. CME Group's dividend payout ratio is currently 50.30%.

Insider Transactions at CME Group

In other CME Group news, Director Martin J. Gepsman sold 300 shares of CME Group stock in a transaction dated Thursday, May 15th. The shares were sold at an average price of $273.17, for a total transaction of $81,951.00. Following the transaction, the director now directly owns 24,767 shares of the company's stock, valued at $6,765,601.39. The trade was a 1.20% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director William R. Shepard bought 256 shares of CME Group stock in a transaction on Wednesday, June 25th. The shares were purchased at an average cost of $270.53 per share, for a total transaction of $69,255.68. Following the completion of the purchase, the director now directly owns 258,196 shares of the company's stock, valued at $69,849,763.88. This trade represents a 0.10% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders have sold 13,400 shares of company stock valued at $3,680,610. Corporate insiders own 0.30% of the company's stock.

Analysts Set New Price Targets

Several analysts recently commented on the stock. Raymond James Financial upgraded shares of CME Group from a "market perform" rating to an "outperform" rating and set a $287.00 price target on the stock in a research report on Monday, March 10th. Keefe, Bruyette & Woods raised their price target on shares of CME Group from $265.00 to $273.00 and gave the company a "market perform" rating in a research report on Thursday, April 24th. Morgan Stanley raised their price target on shares of CME Group from $301.00 to $304.00 and gave the company an "overweight" rating in a research report on Thursday, April 24th. UBS Group raised their price target on shares of CME Group from $290.00 to $305.00 and gave the company a "buy" rating in a research report on Friday, April 25th. Finally, Barclays raised their price target on shares of CME Group from $279.00 to $283.00 and gave the company an "equal weight" rating in a research report on Wednesday, April 23rd. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, CME Group presently has a consensus rating of "Hold" and an average price target of $258.20.

CME Group Profile

CME Group Inc, together with its subsidiaries, operates contract markets for the trading of futures and options on futures contracts worldwide. It offers futures and options products based on interest rates, equity indexes, foreign exchange, agricultural commodities, energy, and metals, as well as fixed income and foreign currency trading services.

Want to see what other hedge funds are holding CME? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CME Group Inc. (NASDAQ:CME - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.